madman
Super Moderator
It should be finally acknowledged that the AR CAG repeat polymorphism plays a role in testosterone replacement therapy of males with hypogonadotropic gonadism since shorter AR gene CAG tract lengths was found to yield greater metabolic improvement in response to testosterone administration.
Conclusion
*in 2015 a large body of evidence indicated an important role for AR CAG polymorphism in conditioning the peripheral effect of testosterone even if its contribution warrants further assessment because of the many controversial findings in each androgen-related action
*at present AR CAG polymorphism is not recommended in the routine setting however in the near future it could become of clinical relevance because of the theoretical possibility of identifying subjects more or less at risk for various disorders more or less responsive to testosterone treatment
*study of CAG repeat length could allow us to individually tailor testosterone replacement therapy as subjects with shorter CAG repeat could need lower doses of testosterone while men with longer repeats could require higher ones
Conclusion
*in 2015 a large body of evidence indicated an important role for AR CAG polymorphism in conditioning the peripheral effect of testosterone even if its contribution warrants further assessment because of the many controversial findings in each androgen-related action
*at present AR CAG polymorphism is not recommended in the routine setting however in the near future it could become of clinical relevance because of the theoretical possibility of identifying subjects more or less at risk for various disorders more or less responsive to testosterone treatment
*study of CAG repeat length could allow us to individually tailor testosterone replacement therapy as subjects with shorter CAG repeat could need lower doses of testosterone while men with longer repeats could require higher ones
